Climbing as an Add-On Treatment Option for Patients with Severe Anxiety Disorders and PTSD: Feasibility Analysis and First Results of a Randomized Controlled Longitudinal Clinical Pilot Trial
Abstract
:1. Introduction
- Individuals who are non-responders or treatment-resistant;
- Individuals from regions where evidence-based interventions are inaccessible or not acceptable (e.g., stigmatization);
- (1)
- Assess the acceptance and feasibility of climbing therapy for patients diagnosed with anxiety disorders and PTSD, including patients with severe mental burden.
- (2)
- Compare the efficacy on health-related aspects, such as symptom severity, between climbing, Nordic walking, and non-exercise social contact control programs.
- (3)
- Assess the possibility of simultaneously collecting biological parameters to identify underlying pathobiochemical mechanisms.
2. Materials and Method
2.1. Study Design and Procedures
2.2. Participants
- (a)
- outpatients with a primary ICD-10 diagnosis based on a clinical judgement of any anxiety disorder or post-traumatic stress disorder (PTSD) (F 40, F 41, F 43.1; ICD-10; World Health Organization),
- (b)
- aged between 18–65 years, and
- (c)
- giving written informed consent.
- (a)
- patients with acute psychosis or suicidal behavior,
- (b)
- medical contraindication to exercise assessed by a clinician,
- (c)
- somatic comorbidity with contraindication to moderate physical activity (e.g., high risk of cardiac events; judged by the patients’ primary care physician),
- (d)
- cognitive deficits (unsuitable to complete the required questionnaires, diagnosed by the referring psychiatrist, psychologist, or psychotherapist),
- (e)
- deficiencies in German language skills (failing to complete the required questionnaires, verbally interact in the social contact group, or understand the instructions given in the exercise groups; this was diagnosed by the referring psychiatrist, psychologist, or psychotherapist).
2.3. Programs
2.3.1. Climbing Exercise
2.3.2. Nordic Walking Exercise
2.3.3. Social Contact Control
2.4. Study Outcomes and Instruments
2.4.1. Parameters for Feasibility and Acceptance of the Climbing Program
2.4.2. Psychological Parameters
2.4.3. Biological Parameters
2.5. Statistical Analysis
3. Results
3.1. Description of Study Participants
3.2. Psychological Parameters
3.3. Biological Parameters
4. Discussion
Strengths and Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Baxter, A.J.; Vos, T.; Scott, K.M.; Ferrari, A.J.; Whiteford, H.A. The global burden of anxiety disorders in 2010. Psychol. Med. 2014, 44, 2363–2374. [Google Scholar] [CrossRef] [PubMed]
- Bandelow, B.; Michaelis, S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin. Neurosci. 2015, 17, 327–335. [Google Scholar] [CrossRef] [PubMed]
- Remes, O.; Brayne, C.; van der Linde, R.; Lafortune, L. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016, 6, e00497. [Google Scholar] [CrossRef]
- Batelaan, N.M.; Seldenrijk, A.; Bot, M.; van Balkom, A.J.L.M.; Penninx, B.W.J.H. Anxiety and new onset of cardiovascular disease: Critical review and meta-analysis. Br. J. Psychiatry 2016, 208, 223–231. [Google Scholar] [CrossRef] [PubMed]
- Mendlowicz, M.V.; Stein, M.B. Quality of life in individuals with anxiety disorders. Am. J. Psychiatry 2000, 157, 669–682. [Google Scholar] [CrossRef]
- Kane, J.C.; Elafros, M.A.; Murray, S.M.; Mitchell, E.M.H.; Augustinavicius, J.L.; Causevic, S.; Baral, S.D. A scoping review of health-related stigma outcomes for high-burden diseases in low- and middle-income countries. BMC Med. 2019, 17, 17. [Google Scholar] [CrossRef] [PubMed]
- Stubbs, B.; Vancampfort, D.; Rosenbaum, S.; Firth, J.; Cosco, T.; Veronese, N.; Salum, G.A.; Schuch, F.B. An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: A meta-analysis. Psychiatry Res. 2017, 249, 102–108. [Google Scholar] [CrossRef] [PubMed]
- Ansara, E.D. Management of treatment-resistant generalized anxiety disorder. Ment. Health Clin. 2020, 10, 326–334. [Google Scholar] [CrossRef]
- Katz, C.; Stein, M.; Don, J.; Seedat, S.; Saree, J. A Review of Interventions for Treatment-Resistant Posttraumatic Stress Disorder. In Different Views of Anxiety Disorders; Selek, S., Ed.; InTech: London, UK, 2011; ISBN 978-953-307-560-0. [Google Scholar]
- Kandola, A.; Vancampfort, D.; Herring, M.; Rebar, A.; Hallgren, M.; Firth, J.; Stubbs, B. Moving to Beat Anxiety: Epidemiology and Therapeutic Issues with Physical Activity for Anxiety. Curr. Psychiatry Rep. 2018, 20, 63. [Google Scholar] [CrossRef]
- Hegberg, N.J.; Hayes, J.P.; Hayes, S.M. Exercise Intervention in PTSD: A Narrative Review and Rationale for Implementation. Front. Psychiatry 2019, 10, 133. [Google Scholar] [CrossRef]
- Schuch, F.B.; Stubbs, B.; Meyer, J.; Heissel, A.; Zech, P.; Vancampfort, D.; Rosenbaum, S.; Deenik, J.; Firth, J.; Ward, P.B.; et al. Physical activity protects from incident anxiety: A meta-analysis of prospective cohort studies. Depress. Anxiety 2019, 36, 846–858. [Google Scholar] [CrossRef]
- Ramos-Sanchez, C.P.; Schuch, F.B.; Seedat, S.; Louw, Q.A.; Stubbs, B.; Rosenbaum, S.; Firth, J.; van Winkel, R.; Vancampfort, D. The anxiolytic effects of exercise for people with anxiety and related disorders: An update of the available meta-analytic evidence. Psychiatry Res. 2021, 302, 114046. [Google Scholar] [CrossRef]
- Rosenbaum, S.; Vancampfort, D.; Steel, Z.; Newby, J.; Ward, P.B.; Stubbs, B. Physical activity in the treatment of Post-traumatic stress disorder: A systematic review and meta-analysis. Psychiatry Res. 2015, 230, 130–136. [Google Scholar] [CrossRef]
- Oppizzi, L.M.; Umberger, R. The Effect of Physical Activity on PTSD. Issues Ment. Health Nurs. 2018, 39, 179–187. [Google Scholar] [CrossRef]
- Bartley, C.A.; Hay, M.; Bloch, M.H. Meta-analysis: Aerobic exercise for the treatment of anxiety disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 45, 34–39. [Google Scholar] [CrossRef]
- Chalder, M.; Wiles, N.J.; Campbell, J.; Hollinghurst, S.P.; Searle, A.; Haase, A.M.; Taylor, A.H.; Fox, K.R.; Baxter, H.; Davis, M.; et al. A pragmatic randomised controlled trial to evaluate the cost-effectiveness of a physical activity intervention as a treatment for depression: The treating depression with physical activity (TREAD) trial. Health Technol. Assess. 2012, 16, 1–164. [Google Scholar] [CrossRef]
- Bichler, C.S.; Niedermeier, M.; Gufler, A.; Gálffy, M.; Sperner-Unterweger, B.; Kopp, M. A case-control study on physical activity preferences, motives, and barriers in patients with psychiatric conditions. Compr. Psychiatry 2021, 111, 152276. [Google Scholar] [CrossRef]
- Karg, N.; Dorscht, L.; Kornhuber, J.; Luttenberger, K. Bouldering psychotherapy is more effective in the treatment of depression than physical exercise alone: Results of a multicentre randomised controlled intervention study. BMC Psychiatry 2020, 20, 116. [Google Scholar] [CrossRef]
- Stelzer, E.-M.; Book, S.; Graessel, E.; Hofner, B.; Kornhuber, J.; Luttenberger, K. Bouldering psychotherapy reduces depressive symptoms even when general physical activity is controlled for: A randomized controlled trial. Heliyon 2018, 4, e00580. [Google Scholar] [CrossRef]
- Schwarz, L.; Dorscht, L.; Book, S.; Stelzer, E.-M.; Kornhuber, J.; Luttenberger, K. Long-term effects of bouldering psychotherapy on depression: Benefits can be maintained across a 12-month follow-up. Heliyon 2019, 5, e02929. [Google Scholar] [CrossRef] [Green Version]
- Luttenberger, K.; Karg-Hefner, N.; Berking, M.; Kind, L.; Weiss, M.; Kornhuber, J.; Dorscht, L. Bouldering psychotherapy is not inferior to cognitive behavioural therapy in the group treatment of depression: A randomized controlled trial. Br. J. Clin. Psychol. 2021, 61, 465–493. [Google Scholar] [CrossRef] [PubMed]
- Leichtfried, V. Therapeutisches Klettern—Eine Extremsportart geht neue Wege. In Alpin-Und Höhenmedizin; Berghold, F., Brugger, H., Burtscher, M., Domej, W., Durrer, B., Fischer, R., Paal, P., Schaffert, W., Schobersberger, W., Sumann, G., Eds.; Springer: Vienna, Austria, 2015; pp. 107–117. ISBN 978-3-7091-1832-0. [Google Scholar]
- Frühauf, A.; Sevecke, K.; Kopp, M. Ist-Stand der Fachliteratur zu Effekten des therapeutischen Kletterns auf die psychische Gesundheit—Fazit: Viel zu tun. Neuropsychiatrie 2019, 33, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Frühauf, A.; Niedermeier, M.; Sevecke, K.; Haid-Stecher, N.; Albertini, C.; Richter, K.; Schipflinger, S.; Kopp, M. Affective responses to climbing exercises in children and adolescents during in-patient treatment for mental health disorders a pilot study on acute effects of different exercise interventions. Psychiatry Res. 2020, 291, 113245. [Google Scholar] [CrossRef] [PubMed]
- Bichler, C.S.; Niedermeier, M.; Hüfner, K.; Gálffy, M.; Sperner-Unterweger, B.; Kopp, M. Affective Responses to Both Climbing and Nordic Walking Exercise Are Associated With Intermediate-Term Increases in Physical Activity in Patients With Anxiety and Posttraumatic Stress Disorder—A Randomized Longitudinal Controlled Clinical Pilot Trial. Front. Psychiatry 2022, 13, 856730. [Google Scholar] [CrossRef]
- Luttenberger, K.; Stelzer, E.-M.; Först, S.; Schopper, M.; Kornhuber, J.; Book, S. Indoor rock climbing (bouldering) as a new treatment for depression: Study design of a waitlist-controlled randomized group pilot study and the first results. BMC Psychiatry 2015, 15, 201. [Google Scholar] [CrossRef]
- Kratzer, A.; Luttenberger, K.; Karg-Hefner, N.; Weiss, M.; Dorscht, L. Bouldering psychotherapy is effective in enhancing perceived self-efficacy in people with depression: Results from a multicenter randomized controlled trial. BMC Psychol. 2021, 9, 126. [Google Scholar] [CrossRef]
- Wolf, M.; Mehl, K. Experiential learning in psychotherapy: Ropes course exposures as an adjunct to inpatient treatment. Clin. Psychol. Psychother. 2011, 18, 60–74. [Google Scholar] [CrossRef]
- Vancampfort, D.; Sánchez, C.P.R.; Hallgren, M.; Schuch, F.; Firth, J.; Rosenbaum, S.; van Damme, T.; Stubbs, B. Dropout from exercise randomized controlled trials among people with anxiety and stress-related disorders: A meta-analysis and meta-regression. J. Affect. Disord. 2021, 282, 996–1004. [Google Scholar] [CrossRef]
- Asmundson, G.J.G.; Fetzner, M.G.; Deboer, L.B.; Powers, M.B.; Otto, M.W.; Smits, J.A.J. Let’s get physical: A contemporary review of the anxiolytic effects of exercise for anxiety and its disorders. Depress. Anxiety 2013, 30, 362–373. [Google Scholar] [CrossRef]
- Hüfner, K.; Galffy, M.; Egeter, J.; Giesinger, J.M.; Arnhard, K.; Oberacher, H.; Gostner, J.M.; Fuchs, D.; Sperner-Unterweger, B. Acute and Chronic Mental Stress Both Influence Levels of Neurotransmitter Precursor Amino Acids and Derived Biogenic Amines. Brain Sci. 2020, 10, 322. [Google Scholar] [CrossRef]
- Gostner, J.M.; Geisler, S.; Stonig, M.; Mair, L.; Sperner-Unterweger, B.; Fuchs, D. Tryptophan Metabolism and Related Pathways in Psychoneuroimmunology: The Impact of Nutrition and Lifestyle. Neuropsychobiology 2020, 79, 89–99. [Google Scholar] [CrossRef]
- Kink, P.; Egger, E.M.; Lanser, L.; Klaunzner, M.; Holzner, B.; Willenbacher, W.; Kasseroler, M.T.; Fuchs, D.; Weiss, G.; Kurz, K. Immune Activation and Anemia Are Associated with Decreased Quality of Life in Patients with Solid Tumors. J. Clin. Med. 2020, 9, 3248. [Google Scholar] [CrossRef]
- Sperner-Unterweger, B.; Kohl, C.; Fuchs, D. Immune changes and neurotransmitters: Possible interactions in depression? Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 48, 268–276. [Google Scholar] [CrossRef]
- Lim, A.; Harijanto, C.; Vogrin, S.; Guillemin, G.; Duque, G. Does Exercise Influence Kynurenine/Tryptophan Metabolism and Psychological Outcomes in Persons With Age-Related Diseases? A Systematic Review. Int. J. Tryptophan Res. 2021, 14. [Google Scholar] [CrossRef]
- Cohen, J. Statistical Power Analysis for the Behavioral Sciences; Routledge: London, UK, 2013; ISBN 9781134742707. [Google Scholar]
- Borg, G. Borg’s Perceived Exertion and Pain Scales; Human Kinetics: Champaign, IL, USA, 1998; ISBN 0-88011-623-4. [Google Scholar]
- Beck, A.T.; Steer, R.A. Manual for the Beck Anxiety Inventory; Psychological Corporation: San Antonio, TX, USA, 1990. [Google Scholar]
- Weathers, F.W.; Litz, B.T.; Keane, T.M.; Palmieri, P.A.; Marx, B.P.; Schnurr, P.P. The PTSD Checklist for DSM-5 (PCL-5); National Center for PTSD: Washington, DC, USA, 2013. [Google Scholar]
- Beck, A.T.; Steer, R.A.; Brown, G.K. Manual for the Beck Depression Inventory-II; Psychological Corporation: San Antonio, TX, USA, 1996. [Google Scholar]
- Meyer, T.J.; Miller, M.L.; Metzger, R.L.; Borkovec, T.D. Development and validation of the penn state worry questionnaire. Behav. Res. Ther. 1990, 28, 487–495. [Google Scholar] [CrossRef]
- Glöckner-Rist, A.; Rist, F. Deutsche Version des Penn State Worry Questionnaire (PSWQ-d). In Zusammenstellung Sozialwissenschaftlicher Items und Skalen (ZIS); ZIS-GESIS Leibniz Institute for the Social Sciences: Cologne, Germany, 2014; Volume 10. [Google Scholar]
- Schwarzer, R.; Jerusalem, M. (Eds.) Generalized Self-Efficacy Scale: Measures in Health Psychology: A User’s Portfolio. In Causal and Control Beliefs; NFER-NELSON: Windsor, UK, 1995. [Google Scholar]
- Group, T.W. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Soc. Sci. Med. 1998, 46, 1569–1585. [Google Scholar] [CrossRef]
- Neurauter, G.; Scholl-Bürgi, S.; Haara, A.; Geisler, S.; Mayersbach, P.; Schennach, H.; Fuchs, D. Simultaneous measurement of phenylalanine and tyrosine by high performance liquid chromatography (HPLC) with fluorescence detection. Clin. Biochem. 2013, 46, 1848–1851. [Google Scholar] [CrossRef]
- Widner, B.; Werner, E.R.; Schennach, H.; Wachter, H.; Fuchs, D. Simultaneous Measurement of Serum Tryptophan and Kynurenine by HPLC. Clin. Chem. 1997, 43, 2424–2426. [Google Scholar] [CrossRef]
- Fuchs, D.; Möller, A.A.; Reibnegger, G.; Stöckle, E.; Werner, E.R.; Wachter, H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J. Acquir. Immune Defic. Syndr. 1990, 3, 873–876. [Google Scholar]
- Capuron, L.; Schroecksnadel, S.; Féart, C.; Aubert, A.; Higueret, D.; Barberger-Gateau, P.; Layé, S.; Fuchs, D. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: Role in neuropsychiatric symptoms. Biol. Psychiatry 2011, 70, 175–182. [Google Scholar] [CrossRef]
- Perneger, T.V. What’s wrong with Bonferroni adjustments. BMJ 1998, 316, 1236–1238. [Google Scholar] [CrossRef]
- Ashdown-Franks, G.; Firth, J.; Carney, R.; Carvalho, A.F.; Hallgren, M.; Koyanagi, A.; Rosenbaum, S.; Schuch, F.B.; Smith, L.; Solmi, M.; et al. Exercise as Medicine for Mental and Substance Use Disorders: A Meta-review of the Benefits for Neuropsychiatric and Cognitive Outcomes. Sports Med. 2020, 50, 151–170. [Google Scholar] [CrossRef]
- Pedersen, B.K.; Saltin, B. Exercise as medicine—Evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand. J. Med. Sci. Sports 2015, 25 (Suppl. 3), 1–72. [Google Scholar] [CrossRef]
- Porcelli, S.; van der Wee, N.; van der Werff, S.; Aghajani, M.; Glennon, J.C.; van Heukelum, S.; Mogavero, F.; Lobo, A.; Olivera, F.J.; Lobo, E.; et al. Social brain, social dysfunction and social withdrawal. Neurosci. Biobehav. Rev. 2019, 97, 10–33. [Google Scholar] [CrossRef]
- Zschucke, E.; Gaudlitz, K.; Ströhle, A. Exercise and Physical Activity in Mental Disorders: Clinical and Experimental Evidence. J. Prev. Med. Public Health 2013, 46, S12–S21. [Google Scholar] [CrossRef] [PubMed]
- Cohen, E.E.A.; Ejsmond-Frey, R.; Knight, N.; Dunbar, R.I.M. Rowers’ high: Behavioural synchrony is correlated with elevated pain thresholds. Biol. Lett. 2010, 6, 106–108. [Google Scholar] [CrossRef] [PubMed]
- Herring, M.P.; Jacob, M.L.; Suveg, C.; Dishman, R.K.; O’Connor, P.J. Feasibility of exercise training for the short-term treatment of generalized anxiety disorder: A randomized controlled trial. Psychother. Psychosom. 2012, 81, 21–28. [Google Scholar] [CrossRef] [PubMed]
- Alexandratos, K.; Barnett, F.; Thomas, Y. The Impact of Exercise on the Mental Health and Quality of Life of People with Severe Mental Illness: A Critical Review. Br. J. Occup. Ther. 2012, 75, 48–60. [Google Scholar] [CrossRef]
- Tschentscher, M.; Niederseer, D.; Niebauer, J. Health benefits of Nordic walking: A systematic review. Am. J. Prev. Med. 2013, 44, 76–84. [Google Scholar] [CrossRef]
- Powers, M.B.; Asmundson, G.J.G.; Smits, J.A.J. Exercise for Mood and Anxiety Disorders: The State-of-the Science. Cogn. Behav. Ther. 2015, 44, 237–239. [Google Scholar] [CrossRef] [Green Version]
Climbing Group (n = 22) | Nordic Walking Group (n = 19) | Social Contact Group (n = 19) | |||||||
---|---|---|---|---|---|---|---|---|---|
Variables | |||||||||
Age in years: M (SD) Med | 44.8 | (13) | 44.5 | 44.7 | (13) | 47.0 | 43.7 | (14) | 45.0 |
Sex: female n, % | 15 | 68% | 16 | 84% | 14 | 74% | |||
State of origin: n, % | |||||||||
Austria | 15 | 68% | 14 | 74% | 13 | 68% | |||
Turkey | 3 | 14% | 2 | 11% | 3 | 16% | |||
Germany | 1 | 5% | 2 | 11% | 3 | 16% | |||
Italy | 2 | 9% | 0 | 0% | 0 | 0% | |||
Other country of origin | 1 | 5% | 1 | 5% | 0 | 0% | |||
Physical activity hours per week: M ± SD, Med | 2.7 | (4) | 1.5 | 2.5 | (3) | 2.0 | 3.4 | (4) | 2.5 |
Body Mass Index: M ± SD, Med | 25.2 | (5) | 23.9 | 26.2 | (7) | 23.4 | 27.4 | (4) | 27.4 |
Bloodpressure systolic: M ± SD, Med | 131.5 | (14) | 130.5 | 136.3 | (22) | 134.5 | 125.6 | (21) | 122.5 |
Bloodpressure diastolic: M ± SD, Med | 84.0 | (10) | 82.5 | 85.7 | (12) | 85.5 | 81.3 | (11) | 79.5 |
Smoking: n, % | 9 | 41% | 8 | 42% | 5 | 26% | |||
Number of cigarettes per day: M ± SD, Med | 11.2 | (6) | 9.0 | 17.7 | (6) | 18.8 | 17.0 | (5) | 20.0 |
Family status | |||||||||
Single/separated/divorced/widowed: n, % | 13 | 59% | 14 | 74% | 9 | 47% | |||
Married/in a partnership: n, % | 9 | 41% | 5 | 26% | 10 | 53% | |||
Number of Children: M ± SD, Med | 1.3 | (2) | 0.0 | 0.7 | (1) | 0.0 | 0.8 | (1) | 1.0 |
Current occupation, yes: n, % | 3 | 14% | 8 | 42% | 0 | 0% | |||
Medication status | |||||||||
Total number of prescription drugs: M ± SD, Med | 2.7 | (1) | 2.5 | 3.4 | (2) | 3.0 | 2.8 | (1) | 2.0 |
Total number of psychopharmacolocial drugs: M ± SD, Med | 1.9 | (1) | 2.0 | 1.9 | (1) | 2.0 | 2.0 | (2) | 2.0 |
Use of psychopharmacolocial drugs, yes: n, % | 18 | 82% | 16 | 84% | 16 | 84% | |||
Use of antidepressant medication: n, % | 19 | 86% | 14 | 74% | 16 | 84% | |||
Use of antipsychotic medication: n, % | 6 | 27% | 7 | 37% | 5 | 26% | |||
Use of benzodiazepines: n, % | 1 | 5% | 5 | 26% | 2 | 11% | |||
Use of anticonvulsives: n, % | 3 | 14% | 5 | 26% | 5 | 26% | |||
Use of other psychopharmacolocigal medication: n, % | 1 | 5% | 0 | 0 | |||||
Diagnoses | |||||||||
Primary diagnosis of an anxiety disorder: n, % | 17 | 77% | 15 | 79% | 11 | 58% | |||
Primary diagnosis of a PTSD: n, % | 4 | 18% | 3 | 16% | 7 | 37% | |||
Primary diagnosis of an anxiety disorder combined with PTSD: n, % | 1 | 5% | 1 | 5% | 1 | 5% | |||
Number of psychiatric diagnosis/comorbidities: M ± SD, Med | 4.4 | (3) | 4.0 | 3.7 | (2) | 3.0 | 3.2 | (2) | 3.0 |
One diagnosis only: n, % | 5 | 23% | 3 | 16% | 2 | 11% | |||
Number of outpatient emergency consultations: M ± SD, Med | 92.4 | (180) | 41.5 | 86.5 | (105) | 56.0 | 60.9 | (54) | 39.0 |
Number of previous psychiatric inpatient treatments: M ± SD, Med | 8.4 | (16) | 3.5 | 4.8 | (6) | 2.0 | 3.9 | (4) | 2.0 |
Years of previous psychiatric treatment: M ± SD, Med | 11.1 | (8) | 13.0 | 9.5 | (8) | 8.0 | 9.8 | (8) | 10.0 |
Descriptives M (SD) | Inferential | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Climbing Group (n = 22) | Nordic Walking Group (n = 19) | Social Contact Group (n = 19) | p-Value | Partial η2 | ||||||||
Variables | M | SD | M | SD | M | SD | Group | Time | Inter-Action | Group | Time | Inter-Action |
Beck Anxiety Inventory_t1 | 21.0 | (12) | 26.3 | (10) | 24.2 | (15) | 0.648 | 0.003 | 0.914 | 0.02 | 0.09 | 0.01 |
Beck Anxiety Inventory_t2 | 18.0 | (12) | 19.4 | (11) | 19.7 | (14) | ||||||
Beck Anxiety Inventory_t3 | 18.9 | (13) | 22.1 | (14) | 21.3 | (16) | ||||||
Beck Anxiety Inventory_t4 | 18.3 | (13) | 22.3 | (16) | 21.2 | (18) | ||||||
Posttraumatic Stress Disorder Checklist_t1 | 45.2 | (13) | 49.3 | (9) | 47.8 | (19) | 0.962 | 0.072 | 0.894 | 0.01 | 0.18 | 0.03 |
Posttraumatic Stress Disorder Checklist_t2 | 40.0 | 24.5 | 40.8 | 26.0 | 41.9 | 24.1 | ||||||
Posttraumatic Stress Disorder Checklist_t3 | 43.2 | 22.9 | 39.8 | 23.9 | 46.3 | 20.8 | ||||||
Posttraumatic Stress Disorder Checklist_t4 | 37.0 | 22.0 | 33.8 | 19.9 | 39.1 | 22.9 | ||||||
Beck Depression Inventory-II_t1 | 25.7 | (11) | 26.0 | (13) | 26.7 | (14) | 0.716 | <0.001 | 0.251 | 0.01 | 0.16 | 0.05 |
Beck Depression Inventory-II_t2 | 18.6 | (11) | 16.8 | (12) | 24.6 | (16) | ||||||
Beck Depression Inventory-II_t3 | 21.4 | (14) | 19.2 | (16) | 22.3 | (16) | ||||||
Beck Depression Inventory-II_t4 | 20.9 | (14) | 18.6 | (14) | 19.9 | (13) | ||||||
Penn State Worry Questionnaire_t1 | 56.0 | (15) | 58.6 | (13) | 55.8 | (14) | 0.854 | <0.001 | 0.290 | 0.01 | 0.12 | 0.04 |
Penn State Worry Questionnaire_t2 | 50.1 | (16) | 53.2 | (12) | 55.1 | (12) | ||||||
Penn State Worry Questionnaire_t3 | 52.5 | (17) | 50.7 | (15) | 54.9 | (10) | ||||||
Penn State Worry Questionnaire_t4 | 50.3 | (17) | 51.1 | (13) | 52.2 | (14) | ||||||
General Self-Efficacy_t1 | 22.8 | (6) | 22.5 | (6) | 21.5 | (7) | 0.543 | <0.001 | 0.108 | 0.02 | 0.11 | 0.06 |
General Self-Efficacy_t2 | 24.6 | (7) | 26.3 | (7) | 22.1 | (7) | ||||||
General Self-Efficacy_t3 | 24.3 | (7) | 25.0 | (6) | 22.6 | (6) | ||||||
General Self-Efficacy_t4 | 23.8 | (6) | 24.9 | (7) | 23.7 | (8) | ||||||
Quality of Life. physical health_t1 | 53.5 | (19) | 48.8 | (22) | 47.5 | (21) | 0.510 | 0.002 | 0.152 | 0.02 | 0.09 | 0.05 |
Quality of Life. physical health_t2 | 56.8 | (19) | 58.0 | (17) | 49.2 | (21) | ||||||
Quality of Life. physical health_t3 | 55.7 | (17) | 60.3 | (22) | 48.5 | (23) | ||||||
Quality of Life. physical health_t4 | 57.7 | (17) | 57.3 | (22) | 55.2 | (23) | ||||||
Quality of Life. psychological health_t1 | 41.1 | (20) | 38.7 | (17) | 40.3 | (21) | 0.728 | 0.006 | 0.128 | 0.01 | 0.08 | 0.06 |
Quality of Life. psychological health_t2 | 45.2 | (22) | 47.5 | (19) | 42.0 | (21) | ||||||
Quality of Life. psychological health_t3 | 45.2 | (23) | 49.5 | (22) | 37.4 | (20) | ||||||
Quality of Life. psychological health_t4 | 47.0 | (24) | 47.3 | (21) | 44.1 | (23) | ||||||
Quality of Life. social relationships_t1 | 57.2 | (26) | 54.4 | (25) | 57.1 | (26) | 0.920 | 0.226 | 0.207 | 0.00 | 0.03 | 0.05 |
Quality of Life. social relationships_t2 | 62.6 | (25) | 59.6 | (25) | 53.6 | (23) | ||||||
Quality of Life. social relationships_t3 | 56.0 | (24) | 57.4 | (25) | 50.1 | (27) | ||||||
Quality of Life. social relationships_t4 | 55.9 | (29) | 59.7 | (24) | 60.4 | (22) | ||||||
Quality of Life. environment_t1 | 67.8 | (15) | 69.9 | (15) | 62.6 | (18) | 0.011 | 0.186 | 0.273 | 0.15 | 0.03 | 0.04 |
Quality of Life. environment_t2 | 68.2 | (15) | 74.4 | (14) | 60.4 | (18) | ||||||
Quality of Life. environment_t3 | 64.8 | (17) | 76.9 | (16) | 57.0 | (17) | ||||||
Quality of Life. environment_t4 | 69.6 | (14) | 77.5 | (18) | 63.5 | (19) |
Climbing Group (n = 16) | Nordic Walking Group (n = 14) | Social Contact Group (n = 15) | p-Value | ||||
---|---|---|---|---|---|---|---|
Variables | M | SD | M | SD | M | SD | |
Kyn/Trp_t1 | 32.0 | (9) | 31.7 | (11) | 33.2 | (6) | 0.948 |
Kyn/Trp_t2 | 32.9 | (10) | 30.4 | (6) | 32.4 | (6) | |
Neopterin_t1 | 7.2 | (3) | 8.0 | (5) | 7.5 | (4) | 0.364 |
Neopterin_t2 | 7.4 | (3) | 7.2 | (3) | 8.5 | (5) | |
Phe/Tyr_t1 | 1.2 | (0) | 1.1 | (0) | 1.1 | (0) | 0.103 |
Phe/Tyr_t2 | 1.2 | (0) | 1.0 | (0) | 1.0 | (0) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bichler, C.S.; Niedermeier, M.; Hüfner, K.; Gálffy, M.; Gostner, J.M.; Nelles, P.; Schöttl, S.E.; Sperner-Unterweger, B.; Kopp, M. Climbing as an Add-On Treatment Option for Patients with Severe Anxiety Disorders and PTSD: Feasibility Analysis and First Results of a Randomized Controlled Longitudinal Clinical Pilot Trial. Int. J. Environ. Res. Public Health 2022, 19, 11622. https://doi.org/10.3390/ijerph191811622
Bichler CS, Niedermeier M, Hüfner K, Gálffy M, Gostner JM, Nelles P, Schöttl SE, Sperner-Unterweger B, Kopp M. Climbing as an Add-On Treatment Option for Patients with Severe Anxiety Disorders and PTSD: Feasibility Analysis and First Results of a Randomized Controlled Longitudinal Clinical Pilot Trial. International Journal of Environmental Research and Public Health. 2022; 19(18):11622. https://doi.org/10.3390/ijerph191811622
Chicago/Turabian StyleBichler, Carina S., Martin Niedermeier, Katharina Hüfner, Mátyás Gálffy, Johanna M. Gostner, Philipp Nelles, Stefanie E. Schöttl, Barbara Sperner-Unterweger, and Martin Kopp. 2022. "Climbing as an Add-On Treatment Option for Patients with Severe Anxiety Disorders and PTSD: Feasibility Analysis and First Results of a Randomized Controlled Longitudinal Clinical Pilot Trial" International Journal of Environmental Research and Public Health 19, no. 18: 11622. https://doi.org/10.3390/ijerph191811622
APA StyleBichler, C. S., Niedermeier, M., Hüfner, K., Gálffy, M., Gostner, J. M., Nelles, P., Schöttl, S. E., Sperner-Unterweger, B., & Kopp, M. (2022). Climbing as an Add-On Treatment Option for Patients with Severe Anxiety Disorders and PTSD: Feasibility Analysis and First Results of a Randomized Controlled Longitudinal Clinical Pilot Trial. International Journal of Environmental Research and Public Health, 19(18), 11622. https://doi.org/10.3390/ijerph191811622